Effect of Universal Test and Treat Strategy on Treatment Outcomes and Patient Survival Among HIV Patients in Addis Ababa, Ethiopia: A Retrospective Cohort Study

For decades, the global fight against HIV relied on a waiting game. Doctors would test people for the virus, but if their immune systems were still holding up well—measured by a specific count of white blood cells called CD4 cells—they were often told to wait before starting medication. The logic was to save the drugs for when the body truly needed them. However, a major shift in thinking occurred around 2016 in Ethiopia, and soon after, in many other places. This new approach, known as "Universal Test and Treat," changed the rule entirely: as soon as a person is diagnosed with HIV, they begin treatment immediately, regardless of how healthy their immune system currently appears. The goal was not just to keep the individual alive, but to stop the virus from spreading to others by lowering the amount of virus in their blood right away. While this strategy made sense on paper, scientists needed to know if it actually worked better for the patients themselves in the real world, specifically whether starting treatment early truly helped people live longer compared to those who had to wait.

To find the answer, researchers in Addis Ababa, the capital of Ethiopia, looked back at the medical records of hundreds of people living with HIV. They focused on a ten-year window, from 2013 to 2023, capturing a time that included years before the new rule and years after it was put into practice. They gathered data from three large public hospitals, reviewing the files of 527 adults who had been on treatment for at least six months. The team split these patients into two groups to compare their journeys. The first group consisted of people who started their medication before the new rule existed; these patients had to wait until their immune counts dropped to a certain level before they could begin. The second group included those who started treatment after the rule changed, meaning they began taking their medicine immediately after diagnosis, without waiting. The researchers then followed the lives of these two groups over time, tracking who was still alive, who had stopped coming for care, and who had passed away.

The results painted a clear picture of the difference between the two approaches. By the end of the study period, nearly 89 percent of all the participants were still alive and continuing their treatment. However, the survival rates were not the same for both groups. Among the patients who started treatment early under the new "Universal Test and Treat" strategy, only about 5 percent had died. In contrast, among the patients who had to wait for their immune counts to drop before starting, the death rate was significantly higher, at nearly 14 percent. The researchers calculated that for every 100 people observed for a year, about 3 people in the waiting group died, while only 1 person in the immediate-treatment group died. When they looked at the survival curves over several years, the group that started treatment immediately stayed alive longer. The statistical analysis confirmed that the risk of death for those who waited was nearly three times higher than for those who started right away.

Beyond the simple comparison of the two groups, the study also identified specific factors that made a person more likely to die, regardless of which group they were in. The most powerful predictor was the state of the patient's immune system at the very beginning. People who started treatment with very low levels of immune cells were far more likely to die than those who started with higher levels. Similarly, patients who were already very sick with other infections or who were too weak to walk on their own when they first arrived at the clinic faced much higher risks. The type of medication they took mattered too; patients who had to take several separate pills rather than a single combined pill were at greater risk of dying. Perhaps most importantly, the study found that how well a patient stuck to their daily medication schedule was critical. Those who missed doses or took their medicine inconsistently were significantly more likely to die than those who took their pills exactly as prescribed. The research also showed that taking preventive medicine for other common infections helped keep patients alive, while developing new infections during treatment was a dangerous sign.

The study concludes that the strategy of starting treatment immediately after diagnosis is not just a policy idea, but a life-saving reality. The data from Addis Ababa shows that moving away from the old practice of waiting for immune counts to drop has directly reduced the number of deaths among people living with HIV. The researchers found that the patients who entered the immediate treatment program survived longer and had better outcomes than those who were treated under the older, delayed system. While the study was limited by the fact that it looked at past records, which can sometimes have missing information, the pattern was strong and consistent. The authors suggest that this approach should be strengthened and used in all health facilities, both public and private, across the country. They emphasize that for anyone diagnosed with HIV, the best path forward is to begin treatment as soon as possible, rather than waiting for the body to show signs of severe illness. This shift in timing, supported by the evidence from these hospitals, offers a clearer path to survival for patients and a stronger shield against the spread of the virus for the community.